A Case Report on Bortezomib-Induced Bilateral Chalazion

Paravathaneni, Mahati; Thota, Vihitha; Mulla, Sana; Thirumaran, Rajesh; Thar, Yu Y

doi:10.7759/cureus.10062

Cited by 2 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Paravathaneni et al reported a case of bilateral chalazion that developed after three cycles of bortezomib-based therapy. Bortezomib therapy was interrupted for 3 weeks, and symptoms improved with conservative measures, and bortezomib was resumed after resolution of symptoms 7. Second-generation proteosome inhibitors such as ixazomib have been administered in cases where rechallenge was not an option due to persistent disease, resulting in successful resolution of chalazion with no evidence of chalazion recurrence on follow-up 8…”

Section: Discussionmentioning

confidence: 99%

Chalazion in a patient with multiple myeloma treated with bortezomib

et al. 2022

View full text Add to dashboard Cite

We present a case of a woman in her early 60s with multiple myeloma who, while undergoing treatment with cyclophosphamide, bortezomib and dexamethasone (CyBorD), noticed a whitish nodular swelling on the eyelid. This occurred after one cycle of CyBorD and on subsequent treatment, it also involved the contralateral eyelid. The lesions were initially managed with conservative measures by applying warm compresses, but the lesions progressively increased in size. CyBorD was discontinued and topical antibiotics and anti-inflammatories were initiated, resulting in a decrease in size of the lesions. On resolution of symptoms, she was rechallenged with CyBorD, and symptoms did not recur. The temporal relationship between bortezomib and the development of chalazion is based on connection and no association has been proven.

show abstract

Section: Discussionmentioning

confidence: 99%